Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-11-13 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于全资子公司产品获得巴西ANVISA认证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding its wholly-owned subsidiary's product receiving certification from Brazil's ANVISA (National Health Surveillance Agency). It details the product information, market situation, and potential impact on the company. The document is short (1239 characters) and focuses on a regulatory approval announcement rather than financial data, management changes, or shareholder votes. It does not contain financial statements or detailed financial analysis. It is not a report or transcript but a regulatory announcement about product certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-11-13 Chinese
关于部分董事、监事持股变动的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding changes in shareholdings by certain company directors and supervisors. It details the share transactions of specific individuals, including the number of shares held before and after the transactions, and the nature of these changes (direct vs indirect holdings). The document explicitly mentions that these changes are due to block trades and clarifies that these do not affect control or the company's ongoing operations. There is no indication of financial results, audit information, or other report types. The content fits the definition of a Director's Dealing report, which covers personal share transactions by company directors and executives (insider trades). The document length is short and focused solely on shareholding changes by directors, confirming it is not a full financial report or other category.
2020-11-13 Chinese
关于持股5%以上股东企业出资额变更的公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement from Shenzhen BGI Genomics Co., Ltd. regarding a change in the capital contribution amount of a shareholder holding more than 5% of shares. It details the reduction in the subscribed capital of the shareholder entity and confirms that this change does not affect the company's governance or shareholder structure. The document is short (1007 characters) and focuses on notifying a change in major shareholding details rather than providing financial statements or detailed analysis. This fits the definition of a Major Shareholding Notification (MRQ).
2020-11-13 Chinese
关于全资子公司产品完成CE认证的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding the completion of CE certification for two HPV detection related products by its wholly-owned subsidiary BGI Europe A/S. It details product information, market context, and potential impact on the company. The document is short (1510 characters) and serves as an announcement of a regulatory milestone rather than a financial report or detailed filing. There is no financial data, no mention of annual or quarterly results, no voting results, no management changes, no legal proceedings, or other report types. It is a regulatory announcement about product certification, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-11-12 Chinese
关于持股5%以上股东减持计划实施完成的公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the completion of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the periods of reduction, and compliance with relevant securities laws and regulations. The document does not contain financial statements or detailed financial performance data but focuses on shareholding changes by a major shareholder. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2020-11-12 Chinese
关于公司申请向特定对象发行股票的审核中心意见落实函的回复
Regulatory Filings Classification · 95% confidence The document is a formal reply from Shenzhen Huada Gene Co., Ltd. to the Shenzhen Stock Exchange regarding the implementation of the review center's opinions on the company's application for a private placement of shares to specific investors. It discusses adjustments to the validity period of the shareholders' meeting resolution related to the private placement, the fulfillment of relevant approval procedures, and information disclosure obligations. The document includes statements from the company's board, independent directors, and the sponsoring institution (CITIC Securities). There are no financial statements or comprehensive financial data presented, nor is this a full report like an annual or interim report. Instead, it is a regulatory response and compliance document related to a capital issuance process. The document length is under 5,000 characters, and it serves as a formal reply to a regulatory inquiry rather than a financial report or announcement of voting results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2020-11-10 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.